Dapagliflozin in Patients with Chronic Kidney Disease
Source: View publication →
In patients with chronic kidney disease, with or without type 2 diabetes, dapagliflozin significantly reduced the risk of kidney failure, cardiovascular events, and all-cause mortality compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
DAPA-CKD was a landmark trial that revolutionized the management of chronic kidney disease by demonstrating that the cardiorenal benefits of SGLT2 inhibitors extend to patients without diabetes. It established dapagliflozin as a foundational, disease-modifying therapy alongside ACE inhibitors and ARBs for the treatment of proteinuric CKD, fundamentally changing nephrology guidelines to incorporate SGLT2 inhibitors as standard-of-care for kidney function preservation.
Historical Context
For nearly two decades following the RENAAL and IDNT trials in the early 2000s, renin-angiotensin system (RAS) blockade was the only approved medical therapy to slow CKD progression. SGLT2 inhibitors, originally developed for glycemic control in type 2 diabetes, demonstrated unexpected cardiovascular and renal benefits in early cardiovascular outcomes trials like EMPA-REG OUTCOME and CANVAS. The CREDENCE trial (2019) subsequently proved canagliflozin's renal benefits, but only in patients with diabetic nephropathy. DAPA-CKD broke new ground by intentionally including a large cohort of non-diabetic CKD patients (e.g., those with IgA nephropathy or hypertensive nephrosclerosis), proving the mechanism of renal protection was hemodynamically driven and independent of glucose lowering.
Guided Discussion
High-yield insights from every perspective
By what mechanism does dapagliflozin provide renoprotection in patients without diabetes, given that its primary mechanism was originally designed to lower blood glucose?
Key Response
This question tests the understanding of tubuloglomerular feedback. SGLT2 inhibitors block sodium and glucose reabsorption in the proximal tubule. The increased sodium delivery to the macula densa triggers afferent arteriolar vasoconstriction. This reduces intraglomerular pressure and hyperfiltration, thereby mitigating mechanical kidney damage and lowering albuminuria, a mechanism entirely independent of its glucose-lowering effects.
A patient with non-diabetic CKD is started on dapagliflozin. Two weeks later, their routine labs show an eGFR drop from 45 to 39 mL/min/1.73m2. How should this initial 'dip' in eGFR be interpreted and managed?
Key Response
This addresses a critical clinical scenario. The initial hemodynamic drop in eGFR is expected due to the reduction in intraglomerular pressure (afferent vasoconstriction). It does not signify acute kidney injury or structural damage. In fact, this initial dip is associated with long-term preservation of renal function. The medication should be continued without dose adjustment or discontinuation.
The DAPA-CKD trial excluded patients with polycystic kidney disease (PKD) and those requiring recent immunosuppression for active glomerulonephritis. Based on the mechanism of SGLT2 inhibitors, why might their efficacy or safety be altered in these specific non-diabetic CKD etiologies?
Key Response
Challenges the fellow to think about the limits of evidence. PKD involves cyst expansion driven by cAMP and fluid secretion; SGLT2 inhibitors might not alter this structural progression and could theoretically alter tubular dynamics unpredictably. For active inflammatory glomerulonephritis (like ANCA vasculitis or lupus), hemodynamic stabilization via SGLT2 inhibition is likely insufficient until active immunological inflammation is controlled, making early inclusion in trials complex and potentially unsafe.
Given the robust mortality and renal benefits demonstrated in DAPA-CKD, how should we conceptualize the 'number needed to treat' (NNT) and the timing of initiation for SGLT2 inhibitors compared to traditional RAS blockade in our clinical practice?
Key Response
Focuses on clinical wisdom and paradigm shifts. The NNT in DAPA-CKD was 19 over 2.4 years to prevent one primary outcome event (a massive benefit). Attendings must teach that SGLT2 inhibitors are no longer just 'diabetes drugs' but foundational 'kidney/heart drugs' that should be initiated early and concurrently with ACEi/ARB therapy, rather than used sequentially as a late-stage add-on when eGFR is already critically low.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The DAPA-CKD trial was stopped early for overwhelming efficacy following a routine interim analysis. What are the statistical and epidemiological risks of stopping a trial early for benefit, and how did the study's statistical design mitigate the risk of overestimating the treatment effect?
Key Response
Explores the 'random high' phenomenon (regression to the mean) in trials stopped early. Early termination can exaggerate effect sizes because trials often stop at random peaks of statistical divergence. The rationale requires discussing the use of strict, predefined stopping boundaries (such as O'Brien-Fleming alpha spending functions) and ensuring a sufficient number of primary events had already accrued to guarantee robust proof beyond random variation.
DAPA-CKD enrolled a highly selected cohort with significant albuminuria (UACR 200 to 5000 mg/g). How does this enrollment criterion limit the external validity of the findings, and what editorial concerns arise when generalizing the 'renoprotective' label to non-proteinuric CKD?
Key Response
Critiques generalizability. Many non-diabetic CKD patients (e.g., hypertensive nephrosclerosis, tubulointerstitial diseases) have low-grade or absent albuminuria (UACR under 200). A rigorous peer reviewer would flag that the profound benefits seen in DAPA-CKD are heavily driven by the proteinuric population, where hyperfiltration is a major driver of progression. Extrapolating this to non-proteinuric CKD requires distinct trial data (which later emerged in EMPA-KIDNEY).
Based on DAPA-CKD demonstrating a mortality and kidney failure benefit in non-diabetic CKD, how should KDIGO guidelines update their recommendations regarding the first-line pharmacological management of proteinuric CKD, and what level of evidence supports this change?
Key Response
DAPA-CKD provides Grade 1A evidence for SGLT2 inhibitors in non-diabetic proteinuric CKD. Historically, KDIGO guidelines positioned ACEi/ARBs as the sole first-line agents for this population. The DAPA-CKD results forced a paradigm shift, leading to updated KDIGO guidelines recommending that SGLT2 inhibitors be added to maximum tolerated RAS inhibitors for patients with eGFR greater than or equal to 20 and UACR greater than or equal to 200, regardless of diabetes status.
Clinical Landscape
Noteworthy Related Trials
CREDENCE Trial
Tested
Canagliflozin 100 mg daily
Population
T2DM patients with CKD and macroalbuminuria
Comparator
Placebo
Endpoint
Composite of ESKD, doubling of serum creatinine, or renal/CV death
DECLARE-TIMI 58 Trial
Tested
Dapagliflozin 10 mg daily
Population
T2DM patients with established CV disease or multiple CV risk factors
Comparator
Placebo
Endpoint
Composite of MACE and composite of CV death or hospitalization for heart failure
EMPA-KIDNEY Trial
Tested
Empagliflozin 10 mg daily
Population
Patients with CKD with or without T2DM and with or without albuminuria
Comparator
Placebo
Endpoint
Composite of kidney disease progression or CV death
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis